49 Results for "

Calcification

" in MedChemExpress (MCE) Product Catalog:
Products (49)

49 Results for "Calcification" in MCE Product Catalog:

Cat. No.: HY-158424
CAS No.: 2565657-20-5
Purity:  99.62%
Target:  

LDLR

Research Areas:  

Cardiovascular Disease

LSN3353871 is an orally active inhibitor of lipoprotein (a) (Lp (a)) formation, with Kd values of 756 nM (apo (a) KIV8), 605 nM (apo (a) KIV7-8), and 423 nM (apo (a) KIV5-8), respectively, and an IC50 of 1.69 μM against apo (a) KIV5-8. LSN3353871 reduces circulating Lp (a) levels in transgenic mice and cynomolgus monkeys. LSN3353871 can be used in the research of atherosclerotic cardiovascular disease and calcific aortic valve disease .
loading...
    loading...
Cat. No.: HY-135517
CAS No.: 891198-31-5
Purity:  99.60%
Synonyms: RXP-470
Target:  

MMP

Research Areas:  

Cardiovascular Disease

RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
loading...
    loading...
Cat. No.: HY-Y0308D
CAS No.: 7558-79-4
Synonyms: Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339
Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .
loading...
    loading...
Cat. No.: HY-158791
CAS No.: 2803505-78-2
Purity:  96.10%
Research Areas:  

Metabolic Disease Cancer

Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively .
loading...
    loading...
Cat. No.: HY-15872
CAS No.: 170006-73-2
FTI-277 is a farnesyltransferase (FTase) inhibitor. FTI-277 inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
loading...
    loading...
Cat. No.: HY-110038
CAS No.: 1217447-06-7
FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
loading...
    loading...
Cat. No.: HY-153335
CAS No.: 2289739-47-3
Purity:  99.11%
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
loading...
    loading...
Cat. No.: HY-112499S
CAS No.: 1233937-31-9
Synonyms: Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7
Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
loading...
    loading...
Cat. No.: HY-112499R
CAS No.: 2124-57-4
Synonyms: Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)
Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
loading...
    loading...
Cat. No.: HY-126304R
CAS No.: 154804-51-0
β-Glycerophosphate disodium salt hydrate (Standard) is the analytical standard of β-Glycerophosphate disodium salt hydrate (HY-126304). This product is intended for research and analytical applications. β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
loading...
    loading...
Cat. No.: HY-116307
CAS No.: 35763-29-2
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
loading...
    loading...
Cat. No.: HY-P991677
CAS No.: 2770242-54-9
Synonyms: INZ-701
Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research .
loading...
    loading...
Cat. No.: HY-124044
CAS No.: 1177148-36-5
Target:  

Phosphatase

Research Areas:  

Cardiovascular Disease

ML 086 is a highly selective PHOSPHO1 phosphatase inhibitor (IC50=0.14 μM). ML 086 is promising for research of hereditary vascular calcification disorders (e.g., generalized arterial calcification of infancy) and spinal ligament ossification .
loading...
    loading...
Cat. No.: HY-109106
CAS No.: 1333218-50-0
Synonyms: SK-1403 free acid; AJT240 free acid; PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-112499S1
Purity:  ≥96.0%
Synonyms: Vitamin K2-7-13C6; Vitamin K2(35)-13C6; Vitamin MK-7-13C6
Menaquinone-7- 13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
loading...
    loading...
Cat. No.: HY-B0561S4
Spironolactone-d6-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
loading...
    loading...
Cat. No.: HY-W014606R
CAS No.: 57282-49-2
L-Lysine (acetate) (Standard) is the analytical standard of L-Lysine (acetate). This product is intended for research and analytical applications. L-Lysine acetate is an essential amino acid. L-Lysine acetate can be research for vascular calcification (VC) and Acute pancreatitis .
loading...
    loading...
Cat. No.: HY-B0302R
CAS No.: 2809-21-4
Synonyms: Etidronate (Standard); HEDPA (Standard); HEDP (Standard)
Research Areas:  

Metabolic Disease Cancer

Etidronic acid,60% in water (Standard) is the analytical standard of Etidronic acid,60% in water. This product is intended for research and analytical applications. Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
loading...
    loading...
Cat. No.: HY-W015370R
CAS No.: 39665-12-8
Squalane (Standard) is the analytical standard of Squalane. This product is intended for research and analytical applications. Squalane, found in certain fish oils (especially shark liver oil), and some vegetable oils, is a saturated derivative of Squalene. Squalane shows anticancer, antioxidant, skin hydrating, and emollient activities .
loading...
    loading...
Cat. No.: HY-119093R
CAS No.: 59831-65-1
Halopemide (Standard) is the analytical standard of Halopemide. This product is intended for research and analytical applications. Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
loading...
    loading...